ライフサイエンスコーパス: synovial sarcoma

1 ene involved in the t(X;18) translocation in synovial sarcoma.

2 osarcoma, malignant fibrous histiocytoma, or synovial sarcoma.

3 study of 243 patients (age range, 6-82) with synovial sarcoma.

4 tologic subtype and the clinical behavior of synovial sarcoma.

5 vity were prognostic factors for survival in synovial sarcoma.

6 atients with HLA-A*02 and MAGE-A4-expressing synovial sarcoma.

7 osarcoma, and one (10%) of ten patients with synovial sarcoma.

8 enomic, and epigenetic mechanisms underlying synovial sarcoma.

9 ESO-1 is commonly expressed, particularly in synovial sarcoma.

10 ESO-1 is commonly expressed, particularly in synovial sarcoma.

11 -perturbed or SMARCB1-null cancers including synovial sarcoma.

12 ith different INI1-negative solid tumours or synovial sarcoma.

13 traditional cytotoxic chemotherapy used for synovial sarcoma.

14 d therapeutic relevance of the SRC kinase in synovial sarcoma.

15 represents a promising therapeutic target in synovial sarcoma.

16 ease stabilization in patients with advanced synovial sarcoma.

17 specific therapeutic interventions to treat synovial sarcoma.

18 el suggest additional nonmyoblast origin for synovial sarcoma.

19 ion of the epithelial structures in biphasic synovial sarcoma.

20 molecules in the tight junction, in biphasic synovial sarcoma.

21 ignificant therapeutic modality for treating synovial sarcoma.

22 expression of ERBB2, IGFBP2, and IGF2 in the synovial sarcomas.

23 e' fusion to SYT, is a consistent feature of synovial sarcomas.

24 t(X;18)(p11;q11) is detectable in almost all synovial sarcomas.

25 n help facilitate the diagnostics of primary synovial sarcomas.

26 Oncoprotein SS18-SSX is a hallmark of synovial sarcomas.

27 ute to the oncogenic activity of SS18-SSX in synovial sarcomas.

28 BH3-peptidomimetic pharmacotherapy in human synovial sarcomas.

29 rs CSK and PTP1B (PTPN1) was conducted in 30 synovial sarcomas.

30 that PDGFRA may be uniquely significant for synovial sarcomas.

31 ve shown preliminary evidence of activity in synovial sarcomas.

32 We analyzed SYT-SSX fusion transcripts in 45 synovial sarcomas (33 monophasic and 12 biphasic) by the

33 re performed on individual tumor samples; 14 synovial sarcomas, 4 malignant fibrous histiocytomas, an

34 desmoplastic small round cell tumors, 2 of 3 synovial sarcomas, 4 of 4 leiomyosarcomas, 1 of 1 malign

35 pid signaling associates with progression of synovial sarcoma, a deadly soft tissue malignancy initia

36 Synovial sarcoma, a soft tissue sarcoma that develops in

37 ation, t(X;18)(p11.2;q11.2), which occurs in synovial sarcoma, a soft tissue tumor.

38 Synovial sarcomas account for up to 10 percent of soft-t

39 The SS18::SSX oncogene is the driver of synovial sarcoma, an aggressive cancer presenting in you

40 gene product, SYT-SSX, routinely detected in synovial sarcoma, an aggressive human tumor.

41 ically subclassified into monophasic spindle synovial sarcoma and biphasic synovial sarcoma with epit

42 acquisition of epithelial characteristics in synovial sarcoma and highlight the potential role of dif

43 malignant tumors, such as parosteal sarcoma, synovial sarcoma and malignant fibrous histiocytoma.

44 ique dependency on GBAF (ncBAF) complexes in synovial sarcoma and malignant rhabdoid tumors, both of

45 ifferentiation, is aberrantly derepressed in synovial sarcoma and may also explain the association of

46 patients with high-risk, primary, extremity, synovial sarcoma and should be considered in the treatme

47 sion oncogene expression characterizes human synovial sarcomas and drives oncogenesis in a mouse mode

48 e expression of apoptotic pathway members in synovial sarcomas and interrogate the impact of modulati

49 nscripts are a defining diagnostic marker of synovial sarcomas and may also yield important independe

50 nslocation t(X;18)(p11.2;q11.2) is unique to synovial sarcomas and results in an 'in frame' fusion of

51 all, 39% (17 of 44; 24-55) for patients with synovial sarcoma, and 25% (two of eight; 3-65) for patie

52 on embryonal and alveolar rhabdomyosarcoma, synovial sarcoma, and adult soft tissue sarcomas diagnos

53 th rare solid tumors such as uveal melanoma, synovial sarcoma, and myxoid liposarcoma.

54 g fibrosarcoma, leiomyosarcoma, liposarcoma, synovial sarcoma, and neurofibrosarcoma cells.

55 lisation (six with Ewing's sarcoma, one with synovial sarcoma, and one with fibrosarcoma) lasting 4 m

56 ere observed in patients with Ewing sarcoma, synovial sarcoma, and osteosarcoma.

57 Synovial sarcomas are aggressive soft-tissue malignancie

58 Synovial sarcomas are aggressive spindle cell sarcomas c

59 Synovial sarcomas are high grade spindle cell tumors tha

60 Primary synovial sarcomas are mainly multilobulated, heterogeneo

61 PURPOSE OF REVIEW: Synovial sarcomas are regarded as chemosensitive tumors

62 lial malignancies, these sarcomas (excepting synovial sarcoma) are characterized predominantly by cop

63 distinct expression profile for the group of synovial sarcomas as compared to the other soft tissue s

64 recent advancements in our understanding of synovial sarcoma biology, the cell-of-origin remains und

65 that is associated with a high proportion of synovial sarcoma can be a useful diagnostic aid.

66 Knowing the main appearance of synovial sarcoma can help facilitate the diagnostics of

67 ssary for maintaining Igf2 expression in the synovial sarcoma cell line, and the increased IGF2 synth

68 man osteoarthritic cartilage as well as by a synovial sarcoma cell line.

69 BRD9 in the G401 rhabdoid tumor and HS-SY-II synovial sarcoma cell lines and had a high degradation s

70 used to immunoscreen cDNA libraries from two synovial sarcoma cell lines and normal testis, resulting

71 Analysis of synovial sarcoma cell lines showed that either IGF-1R or

72 cell growth and migration across a series of synovial sarcoma cell lines.

73 tified selective cytotoxicity of EA in human synovial sarcoma cells (SW982 cells) and investigated th

74 We show that mouse and human synovial sarcoma cells are sensitive in vitro to ABT-263

75 PDGFRA or inhibiting its kinase activity in synovial sarcoma cells blocked rapamycin-induced phospho

76 78, an E3 ligase that is highly expressed in synovial sarcoma cells but relatively underexpressed in

77 xpressing wt p53 compared with CM from human synovial sarcoma cells expressing mutant p53.

78 rved with conditioned medium (CM) from human synovial sarcoma cells expressing wt p53 compared with C

79 mportantly, depletion of SYT-SSX2 in primary synovial sarcoma cells resulted in loss of nuclear beta-

80 We show in human and murine synovial sarcoma cells that SS18-SSX increases BCL2 expr

81 at EA has a potent cytotoxic effect on human synovial sarcoma cells which is mediated by heteromeric

82 Treatment of synovial sarcoma cells with dasatinib led to apoptosis a

83 hromatin remodeling complex, specifically in synovial sarcoma cells, while sparing cardiomyocytes.

84 rid1a or Arid1b (both CBAF-specific) retains synovial sarcoma character, while Smarcb1 (PBAF- and CBA

85 enhanced sarcomagenesis without compromising synovial sarcoma characteristics.

86 ing therapeutic strategy in the treatment of synovial sarcoma; clinical trials are initiating enrollm

87 otein expression in tissue microarrays of 37 synovial sarcomas demonstrated strong expression of ERBB

88 finement of the cell-of-origin revealed that synovial sarcomas derive from a rare Hic1(+) Pdgfra(+) L

89 LOI) for Igf2 in a limited number of primary synovial sarcomas despite demethylation of CpG dinucleot

90 ated cell types, resulting in 100% penetrant synovial sarcoma development in mice, with a median late

91 Despite the name, synovial sarcoma does not typically arise from a synovio

92 Moreover, in a large panel of human synovial sarcomas, enhanced PI3'-lipid signaling also co

93 a, malignant peripheral nerve sheath tumour, synovial sarcoma, epithelioid sarcoma and Ewing sarcoma

94 e mandatory to facilitate the diagnostics of synovial sarcomas, especially for radiolo-gists outside

95 L2 is considered a consistent feature of the synovial sarcoma expression profile.

96 was agreement on the use of chemotherapy for synovial sarcoma, for high-grade tumors, for tumors larg

97 of NCOA3 is essential for SYT-SSX1-mediated synovial sarcoma formation.

98 chromosomal translocation commonly found in synovial sarcomas fuses the SYT gene on chromosome 18 to

99 e that SYT, a partner protein generating the synovial sarcoma fusion protein SYT-SSX, associates with

100 Patients with synovial sarcoma > or = 5 cm in size, microscopic positi

101 nt in the fusion transcript: all 12 biphasic synovial sarcomas had a SYT-SSX1 fusion transcript, and

102 a, dedifferentiated liposarcoma (DDLPS), and synovial sarcoma histological subtype diagnoses, and the

103 yrosine kinases have been found activated in synovial sarcoma; however, no convincing therapeutic con

104 ntly reduced the BRD9 protein by >90% in the synovial sarcoma HS-SY-II xenograft tumor tissue.

105 investigated EZH2 as a therapeutic target in synovial sarcoma in vitro.

106 Previously, we reported modeling synovial sarcomas in mice by conditionally expressing th

107 is review synthesizes recent advancements in synovial sarcoma, including diagnostic pathology, genomi

108 Synovial sarcoma is a cancer driven by a fusion oncoprot

109 Synovial sarcoma is a deadly malignancy with limited sen

110 Synovial sarcoma is a high-grade tumor that is associate

111 Synovial sarcoma is a primitive mesenchymal neoplasm cha

112 Synovial sarcoma is a soft tissue cancer associated with

113 Synovial sarcoma is a soft-tissue malignancy characteriz

114 Synovial sarcoma is an aggressive soft tissue sarcoma ge

115 Synovial sarcoma is an aggressive soft tissue tumor char

116 Synovial sarcoma is an aggressive soft tissue tumor char

117 Synovial sarcoma is an aggressive spindle cell sarcoma w

118 Human synovial sarcoma is caused by a chromosome translocation

119 Like many sarcomas, synovial sarcoma is driven by a characteristic oncogenic

120 ilding the epithelial components in biphasic synovial sarcoma is totally unknown.

121 in the unique translocation t(X;18) found in synovial sarcoma, is known to interact with human BRM (h

122 SYT-SSX2, a fusion also frequently found in synovial sarcoma, is necessary for maintaining Igf2 expr

123 Patients with synovial sarcoma less than 5 cm in size has a cancer-spe

124 ls with altered SWI/SNF complex (e.g., lung, synovial sarcoma, leukemia, and rhabdoid tumors).

125 tissue types leads to exclusive formation of synovial sarcoma-like tumors, whereas its widespread exp

126 ne independent prognostic factors of primary synovial sarcoma localized to the extremity.

127 This review also describes how patients with synovial sarcoma might benefit from future therapy direc

128 , 52 patients with cytogenetically confirmed synovial sarcoma (n=44) and myxoid round cell liposarcom

129 = 7), 0 rhabdomyosarcoma (n = 2), and three synovial sarcomas (n = 22).

130 und cell tumors (including rhabdomyosarcoma, synovial sarcoma, neuroblastoma, Ewing sarcoma, and oste

131 sic and monophasic histological subgroups of synovial sarcoma, notably several keratin genes, and ELF

132 The natural history of primary synovial sarcoma of the extremity is related to tumor si

133 eview, we investigate the main appearance of synovial sarcoma on MRI.

134 Forty-nine percent of patients with synovial sarcoma on the phase II trial of pazopanib had

135 th locally advanced, relapsed, or metastatic synovial sarcoma or myxoid liposarcoma (any grade) were

136 son with atezolizumab alone in patients with synovial sarcoma or myxoid liposarcoma.

137 16-75 years, with metastatic or unresectable synovial sarcoma or myxoid round cell liposarcoma (confi

138 ith HLA-A*02 and MAGE-A4-expressing advanced synovial sarcoma or myxoid round cell liposarcoma.

139 rcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma, osteosarcoma, alveolar soft-part sarco

140 Meta-analysis of human synovial sarcoma patient series identified two tumor-gen

141 Tumor biopsy analyses from a synovial sarcoma patient treated with the mTORC1 inhibit

142 and metastatic sarcoma tissues from a single synovial sarcoma patient were examined for p53-related a

143 The efficacy of lete-cel treatment in 45 synovial sarcoma patients (NCT01343043) has been previou

144 hope for improved treatments and outcomes in synovial sarcoma patients, though challenges remain in o

145 Thus, both in the mouse model and in human synovial sarcomas, PI3'-lipid signaling drives CSF1 expr

146 A subset of synovial sarcoma, predominantly cases with the SYT-SSX1

147 onfirm the distinctive expression profile of synovial sarcoma, provide leads for the study of glandul

148 ural- or neuroectodermal-associated genes in synovial sarcomas relative to the comparison sarcoma gro

149 t(X;18)(p11.2;q11.2) translocation found in synovial sarcomas results in the fusion of the SYT gene

150 nd extensive evaluation for the treatment of synovial sarcoma, rhabdoid tumor, and other BRD9-depende

151 (miR)-183 in multiple tumor types including synovial sarcoma, rhabdomyosarcoma (RMS), and colon canc

152 miR-183 knockdown in synovial sarcoma, RMS, and colon cancer cell lines revea

153 Synovial sarcomas, round-cell/myxoid liposarcomas, clear

154 A tissue microarray containing 37 synovial sarcoma samples verified to bear the SYT-SSX fu

155 onfirmed EZH2 expression in the 76% of human synovial sarcoma samples.

156 secutive patients with extremity and truncal synovial sarcomas seen between 1966 and 1994.

157 Ongoing work on the SYT-SSX fusion and synovial sarcoma should yield a variety of data of broad

158 Additionally, 3 other primary synovial sarcomas showed the following configurations: o

159 eting to polycomb-marked genomic regions and synovial sarcoma-specific dependency on PRC1 function.

160 Almost all patients with synovial sarcoma (SS) carry a characteristic gene fusion

161 Synovial sarcoma (SS) is a rare malignant neoplasm of th

162 Synovial sarcoma (SS) is a rare sarcoma driven by a tran

163 Synovial sarcoma (SS) is an aggressive soft-tissue malig

164 Synovial sarcoma (SS) is an aggressive soft-tissue sarco

165 Synovial Sarcoma (SS) is driven by the SS18::SSX fusion

166 Synovial sarcoma (SS) is the second most common malignan

167 Synovial sarcoma (SS) occurs in both children and adults

168 resent study investigates this hypothesis on synovial sarcoma (SS), assessing the frequency of expres

169 Synovial sarcoma (SS), clear cell sarcoma (CCS), and des

170 e the underlying mechanism, we studied human synovial sarcoma (SS), in which transformation results f

171 liposarcoma (HG-MLPS); leiomyosarcoma (LMS), synovial sarcoma (SS), malignant peripheral nerve sheath

172 c solid tumors expressing MAGE-A4, including synovial sarcoma (SS), ovarian cancer and head and neck

173 The synovial sarcoma (SS)-associated protein, SYT-SSX2, repr

174 umours exhibited high concordance with human synovial sarcoma subtypes at the histological and molecu

175 SUMO2 as a novel, selective vulnerability in synovial sarcoma, suggesting new avenues for targeted tr

176 In contrast to other sarcomas, synovial sarcoma SW982 demonstrated remarkable resistanc

177 Synovial sarcoma (SyS) is an aggressive neoplasm driven

178 Synovial sarcoma (SyS) is an aggressive soft-tissue mali

179 Synovial sarcoma (SySa) is an aggressive soft tissue sar

180 ath tumors (MPNST), solitary fibrous tumors, synovial sarcomas (SySa), well-differentiated/dedifferen

181 in the unique translocation t(X;18) found in synovial sarcoma SYT-SSX fusions.

182 rs) with >or=5 cm, deep, primary, extremity, synovial sarcoma that underwent surgical treatment of cu

183 X fusion oncoprotein (the hallmark driver of synovial sarcoma) that mediates a direct interaction bet

184 In synovial sarcoma, the SS18-SSX fusion protein represses

185 In alveolar rhabdomyosarcoma and synovial sarcoma, these variant fusions have been found

186 h EphB2 and Glu tubulin in SYT-SSX2-positive synovial sarcoma tissues.

187 ic variations in the intrinsic resistance of synovial sarcomas to rapamycin and suggest therapeutic s

188 Expression profiles of 21 claudins in 17 synovial sarcoma tumor samples, including 9 biphasic tum

189 omas with characteristic translocations (two synovial sarcomas, two alveolar rhabdomyosarcomas, two d

190 vestigated the pattern of gene expression in synovial sarcoma using cDNA microarrays containing 6548

191 ic survival rate for patients with localized synovial sarcoma was 34% at 10 years.

192 The mean size of primary synovial sarcoma was 59.3 mm (SD: 42).

193 se-reports assessing MRI features of primary synovial sarcoma was performed.

194 Patients and their primary synovial sarcomas were examined for age, localization, m

195 Primary synovial sarcomas were significantly most often multilob

196 Ovoid/nodular synovial sarcomas were solely depicted as homogeneous wi

197 Fifteen histologically proven primary synovial sarcomas who underwent MRI at 2 different sarco

198 phasic spindle synovial sarcoma and biphasic synovial sarcoma with epithelial components.

199 has been the observation that most cases of synovial sarcoma with glandular epithelial differentiati

200 Patients with synovial sarcoma with less than 10 mitoses per 10 high-p

201 show promise in the treatment of metastatic synovial sarcoma, with 50% overall response rate.

202 Genes of the synovial sarcoma X breakpoint (SSX) family are expressed

203 r types, the cancer/testis Ag encoded by the synovial sarcoma X breakpoint 2 (SSX-2) gene is among th

204 We identified the synovial sarcoma X breakpoint protein (SSX2IP) as a nove

205 ion of a novel centriolar satellite protein, synovial sarcoma X breakpoint-interacting protein 2 (SSX

206 The synovial sarcoma X chromosome breakpoint (SSX) proteins

207 Eventually, synovial sarcoma xenografts were treated with the SRC in